About ViGenCell
ViGenCell is a company based in Seoul (South Korea) founded in 2013 was acquired by Boryung Pharmaceutical in August 2017.. The company has 63 employees as of December 31, 2024. ViGenCell operates in a competitive market with competitors including GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
- Headquarter Seoul, South Korea
- Employees 63 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
- Legal Name Vigencell, Inc.
-
Annual Revenue
$189.15 K (USD)0as on Dec 31, 2024
-
Net Profit
$-9.53 M (USD)21.37as on Dec 31, 2024
-
EBITDA
$-7.93 M (USD)26.82as on Dec 31, 2024
-
Latest Funding Round
- Investors
-
Employee Count
63
as on Dec 31, 2024
-
Acquired by
Boryung Pharmaceutical
(Aug 10, 2017)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of ViGenCell
ViGenCell is a publicly listed company on the KRX with ticker symbol 308080 in South Korea, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Funding Insights of ViGenCell
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in ViGenCell
ViGenCell has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Boryung Pharmaceutical. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Finished formulations and APIs are developed for diverse disease areas.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by ViGenCell
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - ViGenCell
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Vigencell Comparisons
Competitors of ViGenCell
ViGenCell operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of pharmaceuticals and vaccines for various therapeutic areas
|
|
| domain | founded_year | HQ Location |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| domain | founded_year | HQ Location |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
|
|
| domain | founded_year | HQ Location |
Yeast cells are genetically engineered to produce medicinal products.
|
|
| domain | founded_year | HQ Location |
Developing novel drugs based on a proteome-wide ligand and target discovery platform
|
|
| domain | founded_year | HQ Location |
CRISPR-engineered cell and gene therapies are developed for research applications.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Vigencell
Frequently Asked Questions about ViGenCell
When was ViGenCell founded?
ViGenCell was founded in 2013.
Where is ViGenCell located?
ViGenCell is headquartered in Seoul, South Korea.
Who is the current CEO of ViGenCell?
Kim Tae-gyu is the current CEO of ViGenCell.
How many employees does ViGenCell have?
As of Dec 31, 2024, the latest employee count at ViGenCell is 63.
What is the annual revenue of ViGenCell?
Annual revenue of ViGenCell is $189.15K as on Dec 31, 2024.
What does ViGenCell do?
ViGenCell provides therapeutics solution for tumor based on immunological cells. It provides its propriety immunocytochemistry technology to improve the immunity of patients while tumors surgery, drug therapy, and radiotherapy. The leading candidate of the company are ViTier (CTL), ViRager ( γδT ), ViMedier (CBMS) involve in NK T cell lymphoma, acute bone marrow, Blood cancer, glioblastoma, solid cancer, graft-versus-host disease, and others, are in phase 1 and pre-clinical stage.
Who are the top competitors of ViGenCell?
ViGenCell's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.
Is ViGenCell publicly traded?
Yes, ViGenCell is publicly traded on KRX under the ticker symbol 308080.
Who are ViGenCell's investors?
ViGenCell has 1 investor. Key investors include Boryung Pharmaceutical.
What is ViGenCell's ticker symbol?
The ticker symbol of ViGenCell is 308080 on KRX.